Discoveries in Heart Failure
Remote titration may close HFrEF care gaps, especially for older, marginalized patients
CHICAGO — More patients with heart failure achieved target medical doses with remote titration with digital therapeutics vs. usual care, with better efficacy among older vs. younger patients.
Young patients, women benefit from mobile integrated health model for HF
CHICAGO — Mobile integrated health models had greater benefit for younger patients and women with HF despite similar health status and hospital readmissions as transitional care coordinator models, according to MIGHTy-Heart trial findings.
VIDEO: Concomitant tafamidis, acoramidis use does not alter any ATTRibute-CM endpoints
Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis use in conjunction with acoramidis use did not alter the primary efficacy endpoints of the ATTRibute-CM study.
VIDEO: Risk factors for kidney failure after heart transplant similar for men, women
In this video, an expert discusses study results presented at the American College of Cardiology Scientific Session that assessed sex-based differences observed in end-stage kidney disease after heart transplant.
VIDEO: Few women receive counseling, birth control before, after LVAD or heart transplant
In this video, two physicians discuss a study that evaluated the rates of contraceptive prescriptions and counseling in reproductive-aged women before and after left ventricular assist device implant or heart transplant.
RNAi therapeutics improve ATTR amyloidosis with cardiomyopathy survival, functionality
CHICAGO — RNA therapeutics improved survival, 6-minute walk distance and quality of life for patients with transthyretin amyloid cardiomyopathy, according to study results presented at the American College of Cardiology Scientific Session.
IV iron does not reduce time to hospitalization, death for adults with HF, iron deficiency
CHICAGO — Ferric carboxymaltose, an IV iron replacement therapy, did not reduce the time to first HF hospitalization or CV death for patients with HF and iron deficiency, according to results of a late-breaking clinical trial.
Low life-space mobility raises death, hospitalization risk for older patients with HFpEF
CHICAGO — Older adults with HF with preserved ejection fraction and low vs. high life-space mobility had double the risk for all-cause mortality and hospitalization with a higher likelihood of multimorbidity, researchers reported.
Vutrisiran improves cardiac amyloidosis endpoints regardless of disease severity
CHICAGO — Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for a broad spectrum of patients with transthyretin amyloidosis with cardiomyopathy, subgroup analyses show.
Video: SGLT2 inhibitors ‘gaining momentum’ in heart failure treatment
In this video, Lynne Warner Stevenson, MD, discusses new guidelines regarding the use of SGLT2 inhibitors from the American College of Cardiology Scientific Session